Stock Financial Ratios

MYL / Mylan N.V. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price41.45
Volume3,371,200.00
Market Cap ($M)16,845.69
Enterprise Value ($M)31,209.58
Book Value ($M)11,117.60
Book Value / Share20.76
Price / Book1.67
NCAV ($M)-16,086.10
NCAV / Share57.03
Price / NCAV-1.46
Income Statement (mra) ($M)
Revenue11,076.90
EBITDA701.60
Net Income480.00
Balance Sheet (mrq) ($M)
Cash & Equivalents614.90
Cash / Share1.18
Assets0.00
Liabilities22,527.30
Quick Ratio1.01
Current Ratio1.49
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.01
Return on Equity (ROE)0.04
Identifiers and Descriptors
CUSIPN59465109
Central Index Key (CIK)1623613
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
N59465959
010235618
001103120
062853010
0N5946510
N59465909
628530907
628530957
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding520,500,000
Weighted Average Number Diluted Shares Outstanding Adjustment4,900,000
Common Shares Outstanding535,496,988
Weighted Average Number Of Shares Outstanding Basic513,000,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Intangibles Per Share0.00
Accounts Receivable Per Share6.01
Accumulated Depreciation And Depletion Per Share0.00
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Equity Per Share24.82
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share26.88
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Cash Per Share1.18
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Cash And Equivalents Per Share1.15
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Debt Per Share1.48
Liabilities Current Per Share0.00
Inventory Per Share4.76
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Current Per Share13.57
Liabilities Per Share43.28
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00

Peers - Pharmaceutical Preparations (2834)

Related News Stories

How Amazon Could Lose Its Healthcare Bid While Drug Distributor Stocks Win

2018-02-19 seekingalpha
Amazon.com (NASDAQ:AMZN) has been one of the most innovative and disruptive companies of this century, with incredible success in areas that lie outside of what has been historically perceived as its core business (book selling). (557-3)

Theravance Biopharma: Johnson & Johnson Deal Looks Solid

2018-02-18 seekingalpha
The deal with JNJ adds even more credibility to the story, and economics of the pact are generous. (11-0)

BioSci Rounds Report For Feb. 16, 2018

2018-02-18 seekingalpha
FDA approved durvalumab (Imfinzi) for the treatment of stage 3 non-small cell lung cancer (without metastasis and are unresectable). (94-0)

It’s Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to Your Watchlist

2018-02-16 investorplace
Just one day after Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) issued some lackluster guidance followed by news that a competing drug had won the FDA’s approval, TEVA stock got an impressive endorsement. Warren Buffett’s Berkshire Hathaway bought $358 million worth of the beaten-down equity during the fourth quarter of last year. (174-0)

Fresenius: Proven Value Creation Amidst M&A Doubts

2018-01-20 seekingalpha
Shares of Fresenius trade at a discount to peers after the market has doubted the firm's M&A prowess in light of a troubled Akorn acquisition. (103-1)

CUSIP: N59465109